AgeQuant Diagnostic Platform

About 199 Biotechnologies

199 Biotechnologies is an early-stage, private biotech firm developing a novel platform targeting epigenetic damage as the root cause of both cancer and aging. Its core strategy involves three synergistic programs: a lead cancer reprogramming therapy for glioblastoma (E-ON-001), a senolytic compound research program with a lead candidate (Procyanidin C1), and an affordable diagnostic service called AgeQuant. The company aims to transform treatment paradigms from destructive to restorative, offering potentially less toxic and more durable interventions for age-related diseases.

Therapeutic Areas